search
Back to results

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

Primary Purpose

Diabetes Mellitus Type 2

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
BMS-986036
Placebo (Matching with BMS-986036)
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus Type 2

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Diagnosed with type-2 diabetes mellitus with HbA1c ≥6.5% to less than 10.0%
  • Body mass index 30.0 to 50.0

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • Inability to self-administer subcutaneous injections
  • Inability to be venipunctured
  • Evidence of organ dysfunction beyond what is consistent with the target population
  • History of allergy to PEGylated compounds or Fibroblast growth factor 21 (FGF21) related compounds

Sites / Locations

  • Arkansas Clinical Research
  • Anaheim Clinical Trials Llc
  • National Research Institute
  • Encompass Clinical Research
  • Encompass Clinical Research
  • All Medical Research, Llc
  • Central Kentucky Research Associates, Inc.
  • Premier Research
  • Metrolina Internal Medicine
  • Sterling Research Grp, Ltd.
  • Manna Research Vancouver
  • Aggarwal And Associates
  • Rhodin Recherche Clinique
  • Recherche Gcp Research
  • Medexa Recherche
  • Alpha-Recherche Clinique

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Experimental

Arm Label

Treatment A: Placebo (Matching with BMS-986036 - Daily)

Arm 2: Treatment B: BMS-986036 (1 mg Daily)

Treatment C: BMS-986036 (5 mg Daily)

Treatment D: BMS-986036 (20 mg Daily)

Treatment E: BMS-986036 (20 mg Weekly)

Arm Description

Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks

BMS-986036 1 mg subcutaneous injection once daily for 12 weeks

BMS-986036 5 mg subcutaneous injection once daily for 12 weeks

BMS-986036 20 mg subcutaneous injection once daily for 12 weeks

BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks

Outcomes

Primary Outcome Measures

Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Percent Change in Glycosylated Hemoglobin A1c (HbA1c) from Baseline to Week 12 was reported.

Secondary Outcome Measures

Change in Body Weight From Baseline to Week 12
Change in Body Weight from Baseline to Week 12 as a part of Physical measurement was reported.
Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Composite Index of Insulin Sensitivity (CISI) (Matsuda Index)
Whole body insulin sensitivity as quantified by Matsuda Index at the end of the treatment period, calculated by the following equation: 10,000/square root of(FPG*FI)*(FPG+PG30*2+PG60*3+PG120*2)/8*(FPI+PI30*2+PI60*3+PI120*2)/8). FPG=fasting plasma glucose level; FPI=fasting plasma insulin level; PG30,60,90, and 120=plasma glucose levels sampled at 30,60, and 120 minutes after oral glucose load; PI30,60,and 120=plasma insulin levels sampled at 30,60 and 120 minutes after the oral glucose load.
Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Homeostasis model assessment of insulin resistance (HOMA-IR) was used as a validated measure of insulin resistance. HOMA-IR is calculated using the following formula's fasting glucose(mg/dL) x fasting insulin(mU/L) / 405.
Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Quantitative Insulin Sensitivity Check Index (QUICKI)
The Quantitative Insulin Sensitivity Check Index (QUICKI) score, measures insulin sensitivity which is the inverse of insulin resistance. QUICKI is derived using the inverse of the sum of the logarithms of the fasting insulin and fasting glucose: 1 / (log(fasting insulin mU/L) + log(fasting glucose mg/dL)).
Change in Oral Glucose Tolerance Test (OGTT) Area Under the Curve From 0 to 2 Hours for Postprandial Glucose From Baseline to Week 12
Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. Plasma Glucose levels over 2 hours were shown as Area Under the Curve, (AUC).
Change in OGTT Insulin AUC (0-2 Hours) From Baseline to Week 12
Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. Insulin levels over 2 hours were shown as Area Under the Curve, (AUC).
Change in OGTT C-peptide AUC (0-2 Hours) From Baseline to Week 12
Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. C-peptide levels over 2 hours were shown as Area Under the Curve, (AUC).
Average Concentration (Cavg) of C-terminal Intact BMS-986036
Cavg of C-terminal Intact BMS-986036 was reported.
Maximum Observed Concentration (Cmax) of C-terminal Intact BMS-986036
Maximum observed concentration (Cmax) of C-terminal Intact BMS-986036 was reported.
Area Under the Concentration-time Curve From Time Zero to 24 Hours at Steady State (AUC [0-24 Hours, ss]) of C-terminal Intact BMS-986036
AUC [0-24 hours, ss] of C-terminal Intact BMS-986036 was reported.
Area Under the Concentration-time Curve From Time Zero to 168 Hours at Steady State (AUC [0-168 Hours, ss]) of C-terminal Intact BMS-986036
AUC [0-168 hours, ss] of C-terminal Intact BMS-986036 was reported.
Average Concentration (Cavg) of Total BMS-986036
Cavg of Total BMS-986036 was reported.
Maximum Observed Concentration (Cmax) of Total BMS-986036
Maximum observed concentration (Cmax) of Total BMS-986036 was reported.
Area Under the Concentration-time Curve From Time Zero to 24 Hours at Steady State (AUC [0-24 Hours, ss]) Total BMS-986036
AUC [0-24 hours, ss] of Total BMS-986036 was reported.
Area Under the Concentration-time Curve From Time Zero to 168 Hours at Steady State (AUC [0-168 Hours, ss]) of Total BMS-986036
AUC [0-168 hours, ss] of Total BMS- 986036 was reported.
Percentage of Participants With ANTI-BMS-986036 Antibody Response
Percentage of Participants with ANTI-BMS-986036 Antibody Response (ADA positive and ADA Negative) was reported. Participants were monitored for antibodies to BMS-986036 with an anti-BMS-986036 antibody assay. Titers were reported for samples testing positive in an assay.

Full Information

First Posted
March 19, 2014
Last Updated
July 29, 2019
Sponsor
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT02097277
Brief Title
A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
Official Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Obese Adults With Type-2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
April 15, 2014 (Actual)
Primary Completion Date
September 22, 2015 (Actual)
Study Completion Date
May 17, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults with type-2 diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
219 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment A: Placebo (Matching with BMS-986036 - Daily)
Arm Type
Placebo Comparator
Arm Description
Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks
Arm Title
Arm 2: Treatment B: BMS-986036 (1 mg Daily)
Arm Type
Experimental
Arm Description
BMS-986036 1 mg subcutaneous injection once daily for 12 weeks
Arm Title
Treatment C: BMS-986036 (5 mg Daily)
Arm Type
Experimental
Arm Description
BMS-986036 5 mg subcutaneous injection once daily for 12 weeks
Arm Title
Treatment D: BMS-986036 (20 mg Daily)
Arm Type
Experimental
Arm Description
BMS-986036 20 mg subcutaneous injection once daily for 12 weeks
Arm Title
Treatment E: BMS-986036 (20 mg Weekly)
Arm Type
Experimental
Arm Description
BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks
Intervention Type
Biological
Intervention Name(s)
BMS-986036
Intervention Type
Biological
Intervention Name(s)
Placebo (Matching with BMS-986036)
Primary Outcome Measure Information:
Title
Percent Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 12
Description
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Percent Change in Glycosylated Hemoglobin A1c (HbA1c) from Baseline to Week 12 was reported.
Time Frame
Baseline (Day 1) and Week 12
Secondary Outcome Measure Information:
Title
Change in Body Weight From Baseline to Week 12
Description
Change in Body Weight from Baseline to Week 12 as a part of Physical measurement was reported.
Time Frame
Baseline (Day 1) and Week 12
Title
Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Composite Index of Insulin Sensitivity (CISI) (Matsuda Index)
Description
Whole body insulin sensitivity as quantified by Matsuda Index at the end of the treatment period, calculated by the following equation: 10,000/square root of(FPG*FI)*(FPG+PG30*2+PG60*3+PG120*2)/8*(FPI+PI30*2+PI60*3+PI120*2)/8). FPG=fasting plasma glucose level; FPI=fasting plasma insulin level; PG30,60,90, and 120=plasma glucose levels sampled at 30,60, and 120 minutes after oral glucose load; PI30,60,and 120=plasma insulin levels sampled at 30,60 and 120 minutes after the oral glucose load.
Time Frame
Baseline (Day 1) and Week 12
Title
Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Description
Homeostasis model assessment of insulin resistance (HOMA-IR) was used as a validated measure of insulin resistance. HOMA-IR is calculated using the following formula's fasting glucose(mg/dL) x fasting insulin(mU/L) / 405.
Time Frame
Baseline (Day 1) and Week 12
Title
Change From Baseline to Week 12 in Insulin Sensitivity Quantified by Quantitative Insulin Sensitivity Check Index (QUICKI)
Description
The Quantitative Insulin Sensitivity Check Index (QUICKI) score, measures insulin sensitivity which is the inverse of insulin resistance. QUICKI is derived using the inverse of the sum of the logarithms of the fasting insulin and fasting glucose: 1 / (log(fasting insulin mU/L) + log(fasting glucose mg/dL)).
Time Frame
Baseline (Day 1) and Week 12
Title
Change in Oral Glucose Tolerance Test (OGTT) Area Under the Curve From 0 to 2 Hours for Postprandial Glucose From Baseline to Week 12
Description
Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. Plasma Glucose levels over 2 hours were shown as Area Under the Curve, (AUC).
Time Frame
Baseline (Day 1) and Week 12
Title
Change in OGTT Insulin AUC (0-2 Hours) From Baseline to Week 12
Description
Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. Insulin levels over 2 hours were shown as Area Under the Curve, (AUC).
Time Frame
Bseline (Day 1) and Week 12
Title
Change in OGTT C-peptide AUC (0-2 Hours) From Baseline to Week 12
Description
Blood samples were drawn after an overnight fast and standard OGTT from 0 to 120 minutes. C-peptide levels over 2 hours were shown as Area Under the Curve, (AUC).
Time Frame
Baseline (Day 1) and Week 12
Title
Average Concentration (Cavg) of C-terminal Intact BMS-986036
Description
Cavg of C-terminal Intact BMS-986036 was reported.
Time Frame
Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)
Title
Maximum Observed Concentration (Cmax) of C-terminal Intact BMS-986036
Description
Maximum observed concentration (Cmax) of C-terminal Intact BMS-986036 was reported.
Time Frame
Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)
Title
Area Under the Concentration-time Curve From Time Zero to 24 Hours at Steady State (AUC [0-24 Hours, ss]) of C-terminal Intact BMS-986036
Description
AUC [0-24 hours, ss] of C-terminal Intact BMS-986036 was reported.
Time Frame
Pre-dose, 6, 24 hours postdose on Week 8
Title
Area Under the Concentration-time Curve From Time Zero to 168 Hours at Steady State (AUC [0-168 Hours, ss]) of C-terminal Intact BMS-986036
Description
AUC [0-168 hours, ss] of C-terminal Intact BMS-986036 was reported.
Time Frame
Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)
Title
Average Concentration (Cavg) of Total BMS-986036
Description
Cavg of Total BMS-986036 was reported.
Time Frame
Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)
Title
Maximum Observed Concentration (Cmax) of Total BMS-986036
Description
Maximum observed concentration (Cmax) of Total BMS-986036 was reported.
Time Frame
Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)
Title
Area Under the Concentration-time Curve From Time Zero to 24 Hours at Steady State (AUC [0-24 Hours, ss]) Total BMS-986036
Description
AUC [0-24 hours, ss] of Total BMS-986036 was reported.
Time Frame
Pre-dose, 6, 24 hours postdose on Week 8
Title
Area Under the Concentration-time Curve From Time Zero to 168 Hours at Steady State (AUC [0-168 Hours, ss]) of Total BMS-986036
Description
AUC [0-168 hours, ss] of Total BMS- 986036 was reported.
Time Frame
Pre-dose, 6, 24 hours postdose on Week 8; pre-dose on Weeks 1, 2, 4, 6, 8, and 12; post treatment period on Week 13, 15 and 18 (Day 126)
Title
Percentage of Participants With ANTI-BMS-986036 Antibody Response
Description
Percentage of Participants with ANTI-BMS-986036 Antibody Response (ADA positive and ADA Negative) was reported. Participants were monitored for antibodies to BMS-986036 with an anti-BMS-986036 antibody assay. Titers were reported for samples testing positive in an assay.
Time Frame
Baseline and Day 126

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: Diagnosed with type-2 diabetes mellitus with HbA1c ≥6.5% to less than 10.0% Body mass index 30.0 to 50.0 Exclusion Criteria: Any significant acute or chronic medical illness Inability to self-administer subcutaneous injections Inability to be venipunctured Evidence of organ dysfunction beyond what is consistent with the target population History of allergy to PEGylated compounds or Fibroblast growth factor 21 (FGF21) related compounds
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Arkansas Clinical Research
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Facility Name
Anaheim Clinical Trials Llc
City
Anaheim
State/Province
California
ZIP/Postal Code
92801
Country
United States
Facility Name
National Research Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Encompass Clinical Research
City
Spring Valley
State/Province
California
ZIP/Postal Code
91978-1522
Country
United States
Facility Name
Encompass Clinical Research
City
Spring Valley
State/Province
California
ZIP/Postal Code
91978
Country
United States
Facility Name
All Medical Research, Llc
City
Cooper City
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Facility Name
Central Kentucky Research Associates, Inc.
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40509
Country
United States
Facility Name
Premier Research
City
Trenton
State/Province
New Jersey
ZIP/Postal Code
08611
Country
United States
Facility Name
Metrolina Internal Medicine
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28204
Country
United States
Facility Name
Sterling Research Grp, Ltd.
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
Manna Research Vancouver
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6J 1S3
Country
Canada
Facility Name
Aggarwal And Associates
City
Brampton
State/Province
Ontario
ZIP/Postal Code
L6T 0G1
Country
Canada
Facility Name
Rhodin Recherche Clinique
City
Drummondville
State/Province
Quebec
ZIP/Postal Code
J2B 7T1
Country
Canada
Facility Name
Recherche Gcp Research
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H1M 1B1
Country
Canada
Facility Name
Medexa Recherche
City
Victoriaville
State/Province
Quebec
ZIP/Postal Code
G6P 6P6
Country
Canada
Facility Name
Alpha-Recherche Clinique
City
Quebec
ZIP/Postal Code
G3K 2P8
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
30520566
Citation
Charles ED, Neuschwander-Tetri BA, Pablo Frias J, Kundu S, Luo Y, Tirucherai GS, Christian R. Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. Obesity (Silver Spring). 2019 Jan;27(1):41-49. doi: 10.1002/oby.22344. Epub 2018 Dec 6.
Results Reference
derived
Links:
URL
http://www.bms.com/studyconnect/Pages/home.aspx
Description
BMS clinical trial educational resource
URL
http://bms.com/studyconnect/Pages/home.aspx
Description
BMS Clinical Trial Patient Recruiting

Learn more about this trial

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

We'll reach out to this number within 24 hrs